MYC suppression through innovative chemistry

ongoing

"MYSTIC aims to revolutionize cancer treatment by advancing HeloMYC, a novel cell-penetrating protein therapeutic that targets the oncogenic transcription factor MYC. Developed using our innovative reCHEMbinant platform, HeloMYC represents a breakthrough in addressing an ""undruggable"" intracellular target, combining the specificity of protein therapeutics with enhanced cell penetration and stability. MYC, implicated in over 50% of human cancers, has long been considered an elusive target due to its complex protein-protein and protein-nucleic acid interactions and lack of druggable pockets. HeloMYC is a protein based MYC inhibitor that overcomes these challenges and through strategic chemical modifications achieves potent intracellular activity against MYC-driven transcription in cancer cells in preliminary studies. This 18 months project will focus on three key objectives: advancing HeloMYC's preclinical development; expanding and fortifying our IP portfolio to secure a strong market position; and developing a comprehensive commercialization strategy, evaluating spin-off and licensing pathways. The MYSTIC project has the potential to not only provide a powerful new tool against MYC-driven cancers but also to validate a novel approach to developing protein therapeutics against intracellular targets. Success could open new avenues for treating a wide range of diseases with previously undruggable targets, representing a paradigm shift in drug development. By bridging the gap between academic innovation and clinical application, MYSTIC aims to bring hope to millions of cancer patients worldwide and establish a new frontier in precision medicine."